News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search

 


Lung cancer treatment takes another forward step

Note:  Embargoed until 6am, January 9, 2014

Media release

Lung cancer treatment takes another forward step            

Improvements in lung cancer treatment are set to continue with a PHARMAC decision to extend funding for erlotinib (Tarceva) from 1 January 2014.

Erlotinib and another similar drug gefitinib (Iressa) are tyrosine kinase inhibitors (TKIs) that have changed the way aggressive lung cancer is treated, and improved the prospects of people diagnosed with lung cancer.

Ministry of Health data shows that while colon cancer, prostate cancer, breast cancer and melanoma are most commonly diagnosed in New Zealand, the leading cause of cancer deaths is lung cancer.

TKIs are part of a new wave of targeted cancer medicines, which are particularly effective for patients with lung cancer that harbour a particular genetic sequence. Patients are identified using a diagnostic test called epidermal growth factor receptor (EGFR) testing. For people with this type of disease, targetted TKIs offer more effective, less toxic, and more convenient treatment.

Erlotinib was the first TKI to be funded in 2010, and since then access has been improved and widened so that from 1 January 2014, both erlotinib and gefitinib are funded for people who are newly diagnosed and who have not previously had platinum-based chemotherapy.

PHARMAC Deputy Medical Director Dilky Rasiah says the impact of the change in lung cancer treatments is becoming more apparent.

“For patients identified through testing, the TKIs have three major advantages over the chemotherapy treatments they are replacing,” she says.

“Firstly, and most importantly, they are more effective treatments for some patients. Usually when a new cancer drug or class of drugs becomes available, a three or four month improvement is considered a good advance. For the TKIs, the data show that the improvement in disease-free survival, the main marker for cancer treatment benefit, is 9-12 months. So this really is a significant improvement in lung cancer outcomes in New Zealand.”

“In addition to being more effective, TKIs don’t have a lot of the nasty side-effects compared with traditional platinum-based chemotherapy, which is very difficult for patients to tolerate. This means more people can maintain a good quality of life and continue on their treatment for longer, whereas previously people may have had to stop, or skip doses due to side effects, so again we get better outcomes.”


“The other benefit is convenience for patients. The TKIs are oral tablets that patients can collect from their pharmacy and take at home. By comparison, people had to make several journeys to a cancer treatment centre to receive an infusion of traditional chemotherapy. This could be difficult for people living some distance from a cancer treatment centre, and means people being treated with TKIs for cancer can carry on with life, and be with their families at a time when they need support.

“So, in short, having TKIs is a major advance in making effective treatment more available and convenient for patients.”

Dr Rasiah says the benefits also extend to other cancer patients not directly taking TKIs. Because the drugs can be taken at home, this frees up the hospital infusion services for other people needing cancer treatment, so that overall more people can receive funded cancer treatments in public hospitals.

PHARMAC’s decision to widen access to erlotinib, to become a first-line treatment for lung cancer, follows a price reduction by the supplier Roche.

ENDS

© Scoop Media

 
 
 
 
 
Culture Headlines | Health Headlines | Education Headlines

 

Memorabilia: Te Papa Buys Peter Snell Singlet

Te Papa has purchased the singlet worn by Peter Snell at the 1964 Tokyo Olympics at an auction this morning at Cordy’s auction house in Auckland. More>>

ALSO:

Scoop Review Of Books: Women At The Centre

In the first chapter of her epic History of New Zealand Women, Barbara Brookes places a version of the Māori creation story alongside that of the Pākehā colonists, setting the scene for how each society saw women. The contrast is startling. More>>

In Auckland Art Gallery: A Tour Of Duty

I had already started my journey through the exhibited collections when an audio announcement about a guided tour to embark shortly from the foyer was made, I decided to join in. Why not? More>>

Art: ‘Holiday’ Wins IHC Art Awards

An intricate embroidered cushion by Wellington artist Jo-Anne Tapiki has won the 2016 IHC Art Awards and $5000. Jo-Anne started working from IHC’s Arts on High studio in Lower Hutt 18 months ago and this is the first time she has entered the competition. More>>

‘Quasi’: Christchurch Art Gallery Reveals Rooftop Sculpture

Christchurch-born and internationally renowned artist Ronnie van Hout has had a huge hand in Christchurch Art Gallery's latest outdoor installation. More>>

Obituary: Last 28th Maori Battalion A Company Veteran Dies

Charlie Petera, the final surviving member of A-Company of the 28th Maori Battalion has died at his home in Ngataki, Northland last night surrounded by his whanau. He was 91 years old. More>>

ALSO:

Get More From Scoop

 
 

LATEST HEADLINES

 
 
 
 
Health
Search Scoop  
 
 
Powered by Vodafone
NZ independent news